BioCryst Pharmaceuticals, Inc.
BCRXNASDAQHealthcare● Active
$8.43
+$0.02(+0.24%)
Market Cap$1.8B
P/E Ratio—
52W High$11.23
52W Low$6
BioCryst Pharmaceuticals, Inc. (BCRX) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
BCRX · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: May 6, 2026EPS Actual
-$0.03
Est. $0.06 · -150.0%
Revenue
$0.16B
Est. $0.15B · +3.5%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 6, 2026
After Market Close
▼ Miss EPS▲ Beat Revenue
BCRX reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$0.07
Rev. $15.39B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$0.07
Rev. Est.$15.39B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 3, 2026 | $0.14 | — | — | — | $0.19B | — |
| ▼ Q2 FY2026 | May 6, 2026 | $0.06 | -$0.03 | -150.0% | $0.16B | $0.15B | +3.5% |
| ▲ Q1 FY2026 | Feb 26, 2026 | $0.07 | $1.12 | +1500.0% | $0.41B | $0.15B | +168.7% |
| ▼ Q4 FY2025 | Nov 3, 2025 | $0.07 | $0.06 | -14.3% | $0.16B | $0.15B | +5.3% |
| ▲ Q3 FY2025 | Aug 4, 2025 | $0.03 | $0.15 | +400.0% | $0.16B | $0.15B | +9.2% |
| ▲ Q2 FY2025 | May 5, 2025 | -$0.07 | $0.00 | +100.2% | $0.15B | $0.15B | -2.8% |
| ▼ Q1 FY2025 | Feb 24, 2025 | -$0.07 | -$0.13 | -85.7% | $0.13B | $0.13B | +3.9% |
| — Q4 FY2024 | Nov 4, 2024 | -$0.07 | -$0.07 | +0.0% | $0.12B | $0.13B | -8.3% |
Q3 FY2026
Aug 3, 2026
EPS Actual
—
EPS Est.
$0.14
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 6, 2026Miss
EPS Actual
-$0.03
EPS Est.
$0.06
EPS Surpr.
-150.0%
Revenue
$0.16B
Q1 FY2026
Feb 26, 2026Beat
EPS Actual
$1.12
EPS Est.
$0.07
EPS Surpr.
+1500.0%
Revenue
$0.41B
Q4 FY2025
Nov 3, 2025Miss
EPS Actual
$0.06
EPS Est.
$0.07
EPS Surpr.
-14.3%
Revenue
$0.16B
Q3 FY2025
Aug 4, 2025Beat
EPS Actual
$0.15
EPS Est.
$0.03
EPS Surpr.
+400.0%
Revenue
$0.16B
Q2 FY2025
May 5, 2025Beat
EPS Actual
$0.00
EPS Est.
-$0.07
EPS Surpr.
+100.2%
Revenue
$0.15B
Q1 FY2025
Feb 24, 2025Miss
EPS Actual
-$0.13
EPS Est.
-$0.07
EPS Surpr.
-85.7%
Revenue
$0.13B
Q4 FY2024
Nov 4, 2024
EPS Actual
-$0.07
EPS Est.
-$0.07
EPS Surpr.
+0.0%
Revenue
$0.12B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $0.12 | $0.13 | $0.15 | 1 |
| Q3 FY2027 | $0.12 | $0.13 | $0.14 | 1 |
| Q2 FY2027 | $0.10 | $0.11 | $0.13 | 1 |
| Q1 FY2027 | $0.05 | $0.06 | $0.06 | 1 |
| Q4 FY2026 | $0.06 | $0.06 | $0.07 | 1 |
| Q3 FY2026 | $0.03 | $0.04 | $0.05 | 2 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $0.2B | $0.2B | $0.2B | 2 |
| Q3 FY2027 | $0.2B | $0.2B | $0.2B | 2 |
| Q2 FY2027 | $0.2B | $0.2B | $0.2B | 2 |
| Q1 FY2027 | $0.2B | $0.2B | $0.2B | 2 |
| Q4 FY2026 | $0.2B | $0.2B | $0.2B | 2 |
| Q3 FY2026 | $0.2B | $0.2B | $0.2B | 5 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▼ Q2 FY2026 | May 6, 2026 | -150.0% | $9.03 | $8.83 | -2.21% |
| ▲ Q1 FY2026 | Feb 26, 2026 | +1500.0% | $7.55 | $7.90 | +4.64% |
| ▼ Q4 FY2025 | Nov 3, 2025 | -14.3% | $7.32 | $6.86 | -6.28% |
| ▲ Q3 FY2025 | Aug 4, 2025 | +400.0% | $7.95 | $8.73 | +9.81% |
| ▲ Q2 FY2025 | May 5, 2025 | +100.2% | $8.93 | $11.03 | +23.52% |
| ▼ Q1 FY2025 | Feb 24, 2025 | -85.7% | $9.21 | $8.29 | -9.99% |
| ▲ Q4 FY2024 | Nov 4, 2024 | +0.0% | $8.43 | $7.35 | -12.81% |
| ▲ Q3 FY2024 | Aug 5, 2024 | +68.4% | $7.02 | $7.51 | +6.98% |
Q2 FY2026-2.21%
Report Date
May 6, 2026
EPS Beat/Miss
-150.0%
Price Before
$9.03
Price After
$8.83
Q1 FY2026+4.64%
Report Date
Feb 26, 2026
EPS Beat/Miss
+1500.0%
Price Before
$7.55
Price After
$7.90
Q4 FY2025-6.28%
Report Date
Nov 3, 2025
EPS Beat/Miss
-14.3%
Price Before
$7.32
Price After
$6.86
Q3 FY2025+9.81%
Report Date
Aug 4, 2025
EPS Beat/Miss
+400.0%
Price Before
$7.95
Price After
$8.73
Q2 FY2025+23.52%
Report Date
May 5, 2025
EPS Beat/Miss
+100.2%
Price Before
$8.93
Price After
$11.03
Q1 FY2025-9.99%
Report Date
Feb 24, 2025
EPS Beat/Miss
-85.7%
Price Before
$9.21
Price After
$8.29
Q4 FY2024-12.81%
Report Date
Nov 4, 2024
EPS Beat/Miss
+0.0%
Price Before
$8.43
Price After
$7.35
Q3 FY2024+6.98%
Report Date
Aug 5, 2024
EPS Beat/Miss
+68.4%
Price Before
$7.02
Price After
$7.51
Avg Beat Reaction+6.43%
Avg Miss Reaction-6.16%
Beat Rate5 / 8 quarters
Largest Move+23.52% (Q2 FY2025)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: BCRX ends December
BioCryst Pharmaceuticals, Inc. (BCRX) most recently reported earnings on May 6, 2026 for Q2 FY2026, posting EPS of $-0.03 — missing the analyst consensus of $0.06 by -150.0%. The next BCRX earnings date is expected around September 1, 2026.
Each quarter, investors track BCRX earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. BCRX revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
BCRX's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
BCRX earnings · 5 questionsBioCryst Pharmaceuticals, Inc.'s next earnings report is expected around September 1, 2026. BCRX typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; BCRX historically reports after market close (AMC).
BCRX earnings datewhen is BCRX earningsBCRX next earnings datewhen does BCRX report earningsBCRX earnings calendar
▸ Source: FMP · BioCryst Pharmaceuticals, Inc. SEC filings · US GAAP · BioCryst Pharmaceuticals, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026